| abstract |
A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided: wherein W, X, Y, Z, x, R 1 , R 2 , R 3 , x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for the treatment of EGFR-related cancers and biomarkers for predicting responsiveness to LOX inhibitors. |